Pharmafile Logo
Pharmafocus logo
Advanced Search

indacterol

Showing 2 posts of 2 posts found.

FDA delays decision on Novartis’ COPD drug

March 23, 2011
Sales and Marketing COPD, Novartis, Onbrez Breezhaler, QAB149, bronchodilator, chronic obstructive pulmonary disease, indacterol

The FDA has delayed its licence decision on Novartis’ once-daily COPD treatment QAB149 by three months. The review process will …

News

Novartis’ COPD drug recommended for FDA approval

March 10, 2011
Sales and Marketing Arcapta Neohaler, COPD, Novartis, Onbrez Breezhaler, QAB143, chronic obstructive pulmonary disease, indacterol

Novartis has won the backing of an FDA advisory committee for its chronic obstructive pulmonary disease (COPD) treatment QAB149. The …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025